Adaptive Biotechnologies Corporation (ADPT)
$25.28-1.13%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4.0B
- Beta
- 2.10
- P/E (TTM)
- -62.05
- Short % float
- 7.63%
- Days to cover
- 4.4
- SI change
- -12.2%
- 1W
- -6.02%
- 1M
- +2.02%
- vs SPY 1W
- -5.88%
- vs SPY 1M
- -0.49%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 1
- GROWTH
- 9
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-19.6%
REV YoY-
ROE-32.6%
EPS YoY-
ROA-10.0%
GROSS75
OP-12
NET-21
[VALUATION]
P/E TTM-62.05
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B27.90
P/FCF-
EV/EBITDA-268.55
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E287.23
ALTMAN Z-
CURR RATIO4.79
ND/EBITDA-
BETA2.10
Company news
FAQ
- What is LOPJLB’s current signal on ADPT?
- LOPJLB’s latest quantitative signal on Adaptive Biotechnologies Corporation (ADPT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ADPT in?
- Adaptive Biotechnologies Corporation (ADPT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Adaptive Biotechnologies Corporation (ADPT) do?
- Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers se…